VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Nanbiosis, a Scientific-Technological Singular Infrastructure with the participation of VHIR (03/07/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=119&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0119\2015_0119_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Scientific-Technological Singular Infrastructures (ICTS) are big facilities, resources, equipments and services, unique in their fields, dedicated to research and technological development. There are only 29 infrastructures that, for their innovation and quality, have this accreditation. The 1st of July, in the conference room of the Centre d’Investigació i Desenvolupament “Josep Pascual Vila”, a new ICTS was presented: Nanbiosis, an initiative dedicated to biomaterials and nanomaterials, where VHIR participates. This ICTS offers comprehensive services from production and characterization of biomolecules or nanoparticles to their preclinical evaluation. Biomaterials are materials designed to manufacture components, parts or appliances to apply to living beings. They are used to evaluate, treat, improve or replace a tissue, organ or function of the body. On the other hand, nanomaterials have other functions beyond living beings and, due to their size, they present particular properties. Nanbiosos will serve to design and produce biomaterials and nanomaterials, and to prepare nanoconjugations and do physicochemical, functional, toxicological and biological characterizations that allow biomedical applications (IDV, biosensors, regenerative medicine, therapeutic and contrast agents, and medical devices). Nanbiosis is composed of CIBER-BBN and the Centro de Cirugía Mínima Invasiva Jesús Usón (CCMIJU), and is distributed in 5 Autonomous Communities (Aragon, Catalonia, Extremadura, Madrid, Basque Country and Valencia). Nanbiosis has 27 units (20 from CIBER-BBN and 7 from CCMIJU). VHIR is part of this ICTS through the Plataforma de Experimentación in vivo (Unit 20), headed by Dr. Simó Scwhartz Jr. and coordinated by Dr. Ibane Abasolo. This unit involves the Molecular Imaging Platform at VHIR and is managed by the Functional Validation &amp; Preclinics (FVPR) area of the CIBBIM-Nanomedicine. “The singularity of this ICTS is that it is formed by different units around the country but the users can access all the offered services from a single attention point” said Dr. Ibane Abasolo, and added: “For VHIR it is very important because it is situated on the map of ICTS, where there are only the most innovative and excellent centers of the country, as the Gran Telescopio de Canarias or the Sincrotró ALBA”. </td></tr></table>comunica@vhir.org (VHIR)Fri, 3 Jul 2015 00:00:00 GMTText DIDAC to 28014 to collaborate with the research on primary immunodeficiency diseases (30/06/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=118&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0118\2015_0118_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> 'Tots amb Didac' (“We are all with Didac” in&nbsp; English) is a campaign started by Didac's parents. Didac is a 4 year-old boy suffering from a primary immunodeficiency disease (PIDD), also called rare diseases, caused by an&nbsp;&nbsp; impaired immune system. In the framework of the campaign, by texting DIDAC to 28014 you can help to continue researching to find solutions to similar diseases affecting Didac, the same that suffered his brother, who died when he was only 3 years old. The aim is double: his parents want to raise public awareness and funds to research on this group of diseases just as they have been doing for the past two years.&nbsp; Through&nbsp;&nbsp; research on PIDDs and thanks to all the donations from the anonymous people, the&nbsp; mutation causing Didac's gene defect has been found; as a matter of fact, he has recently undergone a successful bone marrow transplantation. PIDDs affect the immune system due to a gene defect that would predispose affected patients to a larger number of infections and more severe ones than normally and to various complications including lymphomas and leukaemias, and even to a fatal outcome. Iván, Didac's father, explains: “these diseases are not rare because they are difficult to cure, but because enough research has not been directed”. This is the reason why they are struggling to raise funds, so the SMS text system can help to do research with a higher budget. The Infection in Immunocompromised Pediatric Patients group, where Dr. Pere Soler (the doctor in charge of Didac's case) is a member, and the Immnunology group at Vall d’Hebron Institute of Research (VHIR) are studying PIDDs. Both groups have direct link to VHIR's Pediatric Infectious Diseases Unit, which has nearly 700 diagnosed patients and it is considered a unique and leading centre in this field. &nbsp;&nbsp;&nbsp;&nbsp; All the funds raised through the solidary SMS and donations will be earmarked for the research on primary immunodeficiencies at VHIR. These funds will be specifically invested in collection and preservation of blood samples taken at the hospital through the Immunology Bank of the HUVH Biobank.&nbsp; Why is it so important to collect and preserve the samples? <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-decoration: no</td></tr></table>comunica@vhir.org (VHIR)Tue, 30 Jun 2015 00:00:00 GMTThe Infectious Diseases group has been awarded for a project that seeks new strategies to treat antimicrobial resistant infections (29/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=116&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0116\2015_0116_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) has awarded on of the 2015 Communication Prize for the project entitled “Eficacia de colistimetato de sodio cargado en nanopartículas lipídicas (CMS-NLC) contra P. aeruginosa multiresistentes (MR-PA)”, presented by Jana Basas from the Infectious Disease Group at Vall d’Hebron Institute of Research (VHIR) led by Dr. Benito Almirante. The study was done in collaboration with Universidad del País Vasco (UPV/EHU), Fundació d'Investigació Sanitària de les Illes Balears Ramón Llull  (FISIB) and CSIC. The project is part of a novel Research Area based on “Nanoantimicrobials for Antimicrobial Resistance Infections” led by Dr. Joan Gavaldà. Dr. Gavaldà comments “Access to effective antibiotics is essential in all health systems. Their use has reduced childhood mortality and increased life expectancy, and they are crucial for invasive surgery and treatments such as cancer chemotherapy and solid organ transplantation. Antimicrobial Resistance (AMR) is a concept rather than a disease in itself and despite its dramatic rising, is not given the same attention as acute infectious threats like SARS, Pandemic flu or Ebola, nor the same attention as the three major infectious diseases HIV, Tuberculosis and malaria. AMR is a serious global menace, affecting global economical, social and public health. The most recent World Economic Forum Global Risks reports have listed AMR as one of the greatest societal risks threats to human health.&nbsp; AMR is not only costly in terms of human suffering but also in monetary terms. AMR currently claim at least 50,000 lives each year across Europe and the US alone; at the estimated cost of more than 1.5 billion EUR or 35$ billion annually. In addition to a greater resistance to existing agents, there is a lack of new antibiotics in development. Recently,<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color</td></tr></table>comunica@vhir.org (VHIR)Mon, 29 Jun 2015 00:00:00 GMTWe have more than 1,000 Friends of Vall d'Hebron research (26/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=115&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0115\2015_0115_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Thank you very much on behalf of the researchers of the VHIR and, particularly, of the 5 young researchers who are enjoying a grant to do research thanks to the generosity of Vall d’Hebron’s Friends. We are celebrating that have reached more than 1,000 Friends! 2 years ago, we embarked on the adventure of looking for the first Friends with the creation of the Fundraising Unit. We knew that patients, families and people aware of the importance of research wanted to help us to do research in order to heal diseases, but they didn’t know how to do it regularly. For that reason and to channel the donations we had been receiving it was created the website  www.amicsvallhebron.org (www.amigosvallhebron.org in Spanish). “Before being a Friend of Vall d’Hebron I had been in solidarity with other causes but never with the research. Now I’m very happy because I’m helping the research to advance and these young researchers to have an opportunity”, said Guadalupe, a retired teacher who encourages her former students to do internships at VHIR. The new website opened the door to the society to collaborate with every minute of biomedical research we do in Vall d’Hebron through four ways: as a Friend of Vall d’Hebron, doing a periodical donation for the Institute or for a specific research group; as a donator, doing a punctual donation; as a donator of a charity legacy, or organizing a charity event to raise funds to improve health of the present and the future. At the same time, we started with informative campaigns in the Hospital facilities to have new Friends, what have brought us the opportunity to arrive to many people aware of the importance of research to find the way to heal diseases. “A few years ago they offered me the possibility of participating in a clinical trial at Vall d’Hebron related to a heart disease I have. I accepted because I wanted to collaborate wand help them to investigate my disease in the laboratories”, tells us José Luis, another altruistic Friend of Vall d’Hebron. In his case, he has helped the research through two different ways: as a Friend and as a patient participating in a clinical trial. <p style=" t</td></tr></table>comunica@vhir.org (VHIR)Fri, 26 Jun 2015 00:00:00 GMTLack of microbial diversity: a risk factor for chronic disease (25/06/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=114&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0114\2015_0114_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Research on human microbiome is the new paradigm for prevention and management of chronic disease. According to experts meeting today and tomorrow at the B.Debate (International Center for Scientific Debate), at Cosmocaixa, the lack of microbial diversity is a risk factor for developing specific diseases such as type 2 diabetes, cancer and obesity. This is an initiative by Biocat and&nbsp; "La Caixa" Foundation. The Vall D'Hebron Institute of Research (VHIR), the University of Vic - Central University of Catalonia, the AIDS Research Institute IrsiCaixa and the Spanish&nbsp; National Cancer Research Centre (CNIO) are also collaborating institutions.&nbsp; There are 10 bacteria for each cell of our body, which represents a very important part in terms of health and disease. These organisms even affect in disease manifestation which until today was believed to depend entirely on the human genome. "People whose microbiome is metabolically more active and who have more genetic diversity are healthier people",&nbsp; points out Dr. Francisco Guarner, researcher and member of the group of the Physiology and Pathophysiology of the Digestive Tract group at VHIR. Since the Second World War, the industrialised societies have developed a number of diseases that were not so common before such as type 2 diabetes, hypertension and other cardiovascular disease, austism, obesity, colorectal cancer, etc. Loss of human microbiome diversity would explain reactions such as allergies or celiac disease which means that our body is reacting against bacteria we can find present in the environment but not in our body regularly. "Research on microbiome is facing a fascinating moment", notes Núria Malats, leader of the Genetic and Molecular Epidemiology group at the Spanish National Cancer Research Centre (CNIO). Núria, specialist in pancreatic cancer, believes that bacteria can also be useful to explain specific molecular mechanisms in cancer and that they can become the key to understand some cases of inheritance. "I hope that microbiome will determine risk populations and cancer prognostic markers", she concluded. The thing is that biomedical research has turned its attention to the possibility </td></tr></table>comunica@vhir.org (VHIR)Thu, 25 Jun 2015 00:00:00 GMTThe 'TeleIctus Móvil' project from VHIR wins the Prize Vodafone for the innovation in telecommunications (22/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=112&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0112\2015_0112_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The jury of the IX Edition of the Vodafone Prizes for the Innovation in Telecommunications rewarded three innovative projects in the field of TIC for the social action this year, each one with a prize of 20,000 Euros. The project “TeleIctus Móvil”, presented by Dr. Marc Ribó, from the Stroke Unite at HUVH and member of the Neurovascular Diseases group at VHIR, has won in the category of “Solución TIC Mobile for Good”, which rewarded projects ready for the implementation phase. “TeleIctus Móvil” is for patients suspecting they have suffered a stroke. The tool allows a neurologist to make an early valuation in situ thanks to a videoconference, and also permits to localize the patients in a map and to see how long it will take them to go to a hospital. The tool also shows the Hospital’s assistance level and the treatments available in each one.&nbsp;&nbsp;&nbsp; To elect the winners, the jury has valuated how innovative the project is, the people that can be benefited with the solution purposed, its viability and its accessibility. Two other projects have been rewarded: the Asturian project “Lazzus”, presented by NeoSenTeC, and the project “Visualfy”, developed by the Valencian company Fusió d’Arts Technology. “Lazzus”, which will be available in a few weeks for Android or iOS, is an application to help people with visual impairment to discover what is around them, generating an artificial field of vision that transmits sound information and offering geolocation and a searcher of interesting points. “Lazzus” wins in the category of “Aplicación Mobile for Good”, which rewarded the Smartphone’s application that better improve the quality of life, personal autonomy or promotion of active ageing. On the other hand, “Visualfly” wins in the category of “M2M Mobile for Good”, which rewarded the projects that use or design connected devises to improve the quality of life, accessibility and autonomy of people. This project collects audio information from the environment to convert it into visual and sensory signals, including messages in video in sign language for people with hearing problems. </td></tr></table>comunica@vhir.org (VHIR)Mon, 22 Jun 2015 00:00:00 GMTDr. Colomina and Dr. Bagó awarded with the best oral communication at GEER 2015 (18/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=107&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0107\2015_0107_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Maria José Colomina and Dr. Joan Bagó, members of the Spine Research Unit at VHIR have been awarded with 3,000 euros by the best oral communication at GEER 2015, the Congress of the Spanish Society of Spine. Researchers have received this recognition for their work "Multicenter randomized placebo-controlled clinical trial to evaluate the efficacy and safety of perioperative tranexamic acid in transfusion requirements and surgery bleeding in spinal surgery." The clinical trial was conducted in four Spanish hospitals, including Vall d'Hebron University Hospital, over a total of 95 patients. The results proved that tranexamic acid significantly reduces perioperative bleeding and transfusion requirements in adult patients undergoing major surgery of the spine, with an adequate safety profile. The study was funded between 2010 and 2014 by the Ministry of Health, Social Services and Equality, and directed by Dr. Maria José Colomina. The principal investigator received the award at the congress held recently in Malaga, together with Dr. Bagó and the head of the Spine Research Unit, Dr. Ferran Pellisé. This work is also nominated to the Hibbs Award of the Scoliosis Research Society, which this year will take place in Minneapolis (Minnesota, USA) in October. </td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Jun 2015 00:00:00 GMTEl VHIR dóna suport a la declaració de la Societat Catalana de Biologia a favor de les vacunes (17/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=111&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0111\2015_0111_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> El Vall d'Hebron Institut de Recerca (VHIR) d'adhereix a la declaració sobre vacunacions que ha escrit el Dr. Jordi Barquinero, cap del grup de Teràpia Cel·lular i Gènica, per a la Societat Catalana de Biologia. Aquest és l'escrit: "Probablement no hi ha cap àmbit en el qual el vell aforisme «val més prevenir que curar, però, per prevenir, cal primer educar» sigui més vàlid que en el de la medicina, i més concretament en el de la vacunació. Respecte al paper que les vacunes han tingut en la nostra salut en els darrers dos segles, hi poden haver opinions i sensibilitats molt diferents, fins i tot dins de la comunitat mèdica, però ningú que cregui en el mètode científic —aquesta eina que ens permet passar-ho tot pel sedàs de la comprovació (si pot ser experimental) i l’anàlisi matemàtica més rigorosa— i en la ciència com el gran motor del progrés no s’atreveix a negar que la vacunació sistemàtica de la població ha tingut, i continua tenint, una importància crucial. Pocs avenços mèdics poden presumir d’haver eliminat de manera definitiva una malaltia letal com va ser la verola, que va causar estralls fins que l’Organització Mundial de la Salut la va declarar oficialment eradicada el 1979; reduir a xifres anecdòtiques els casos de poliomielitis, o d’haver salvat la vida de mil cinc-cents milions de persones, segons les estimacions més recents. Per això és difícil d’entendre que en molts països, principalment de l’anomenat primer món, hagi sorgit tanta oposició al seu ús, i que algunes veus les hagin difamat i demonitzat atribuint-los una sèrie d’efectes adversos que en la major part de casos no tenen cap fonament. És cert que ocasionalment s’han produït complicacions, de vegades mortals, com a conseqüència de l’ús d’algunes vacunes. També ho és que la indústria farmacèutica té com a principal objectiu el benefici econòmic, i que exerceix pressió perquè es facin servir o consumeixin els seus productes, però no oblidem que aquesta mateixa indústria és la primera interessada en el fet que el que fabrica i ven funcioni bé. Potser la millor prova de l’eficàcia dels programes de vacunació és que en els països en què no existeixen o no arriben bé a la població es produeixen epidèmies que es cobren milers de vides cada any, en comparació amb els països en què sí es vacuna d’una manera massiva. D’altra banda, en els últims anys la disminució en el nombre de persones vacunades en països desenvolupats, com a conseqüència principalment dels moviments antivacunes, ha creuat una prima línia vermella i ha donat lloc a l’aparició de brots epidèmics de malalties com el xarampió o la tos ferina en llocs com els Estats Units o Europa. El cas de diftèria</td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Jun 2015 00:00:00 GMTDr. Israel Molina wins ex aquo the Prize Young Researcher from ICS (16/06/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=109&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0109\2015_0109_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Israel Molina, from the research group in Infectious Diseases at Vall d’Hebron Research Institute (VHIR) and head of the International Health Program of the Institut Català de Salut (PROSICS), has wan ex aequo the Prize Young Researcher from ICS. The recognition was received at the 7th Research Day of ICS, this year dedicated to infectious diseases. Dr. Molina (Barcelona, 1974) is a doctor specialized in intern medicine and, now, heads at the VHIR and at the PROSICS various research projects. Among them the European project Berenice stands out, which is looking for a more efficient and less toxic medicine for Chagas disease using nanotechnology. He has been working in Africa (Angola) many times and he has built up a strong relationship with the Hospital Nostra Senhora da Paz de Cubal. He has also been working on Brazil, thanks to a grant, and has done many different studies in collaboration with other tropical medicine research institutes.&nbsp; The same award was given to Dr. Oriol Bestard from the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). The same day, Dr. Francesc Gudiol, director of the program Monitoring Nosocomial Infections in Catalan Hospitals (VINCAT) from the Health Department and researcher from IDIBELL received an award for his scientific trajectory. 7th Research Day of ICS 250 researchers from 7 research institutes related to hospitals or primary health care centers talked about the newest scientific achievements in the field of infectious diseases. Dr. Benito Almirante, head of the research group in Infectious Diseases at VHIR, moderated a panel session on bacterial resistance, where Dr. Maria Nieves Larrossa, researcher from the group of Microbiology at VHIR, participated.&nbsp; The main points of the Day were, first, the advances intended to have faster methodology for the diagnosis of the antibiotics’ resistance and sensibility (to be able to choose the best antibiotic in each case) and the review</td></tr></table>comunica@vhir.org (VHIR)Tue, 16 Jun 2015 00:00:00 GMTAlbert Bosch Foundation and GECA donate 10,500 euros for child cancer research (15/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=108&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0108\2015_0108_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Albert Bosch Foundation and the Catalan hiking and cultural group called GECA visited today the Vall d’Hebron University Hospital to give the 10,500 euros raised with the registrations of the Cames de Ferro race, in order to contribute to the research in child cancer, fetal surgery and erythematosus lupus. GECA’s president, Sergi Plana; the organizer of the Mountain Marathon, Pere Gelis;&nbsp; and Noel Alimentaria’s directors, Joan Boix and Anna Bosch, delivered the funds collected to doctors Josep Sánchez de Toledo, head of the Translational Research group in Cancer during childhood and youth, and Josep Ordi, head of the research group in erythematosus lupus. The first edition of the mountain marathon, organized by GECA and sponsored by Noel Alimentària, was a success, with nearly 400 participants: 200 in the 10-km race, 150 in the half marathon and 50 in the marathon. The race passed by some emblematic spots of the Puigsacalm Mountain. The Albert Bosch Foundation was created with the aim to open new opportunities for children with diseases and their families. For 10 years, the foundation has been collaborating closely with VHIR in three research lines: fetal surgery, child cancer and rare diseases such as erythematosus lupus. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Jun 2015 00:00:00 GMTInternational collaboration between VHIR and UAB for Cerebral Infarction treatment (10/06/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=105&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0105\2015_0105_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Neurovascular Diseases group of Vall d'hebron Institute of Research (VHIR) and the Institut de Neurociències UAB have signed a collaborative agreement with the Japanese company R-Tech Ueno, to develop a novel VAP-1 inhibitor for treatment of cerebral infarction. RTU-009 is a novel VAP-1 inhibitor, having an anti-inflammatory and neuroprotective effect. It is confirmed that RTU-009 has a neuroprotective effect similar to Edaravone, the brain protective agent, and a cerebral dysfunction improving effect when applied in combination with t-PA treatment in animal stroke models. It&nbsp; is currently&nbsp; undergoing non-clinical studies to proceed to Phase I clinical&nbsp; trials. Though an oral VAP-1 inhibitor named RTU-1096 is under development, RTU-009 is the novel VAP-1 inhibitor that has been developed as an injection agent targeting for treatment of acute cerebral infarction. To&nbsp; explore the&nbsp; possibility&nbsp; of the clinical application of RTU-009 for treating cerebral infarction as a POC (Proof of&nbsp; Concept) trials (Early&nbsp; Phase&nbsp; II&nbsp; clinical&nbsp; trials),&nbsp; we started collaborative research using stroke animal models with the group led by Professor Unzeta of the Institute of Neuroscience, UAB, and the group led by Dr. Montaner, of Vall d’Hebron Institute of Research, the research centre of the UAB-affiliated Vall d'Hebron University Hospital, who are active in the front line of clinicalas well as research activity. Going forward, they will proceed with the development of RTU-009 as acombinationwith t-PA treatment for acute cerebral infarction as the top priority target. These&nbsp; initiatives, including early clinical trials, will be conducted in collaboration with academia. For&nbsp; the&nbsp; acute stage of cerebral infarction,&nbsp; thrombolytic&nbsp; treatment&nbsp; usingt-PA is&nbsp; the&nbsp; first-line&nbsp; therapy;however,t-PAcan only be used for patients within 4.5 hours from the onset of stroke, considering the risk of brain hemorrhage. Therefore, it is extremely important to develop a new treatment method that reduces the risk of brain hemorrhage and enlarges the range of target patients. According to somereports, the recovery rate, representing the rate of patients who recover to the level of self-reliance, with t-PA treatment is 40-50% in Japan. Further enhancement of the recovery rate and expansion of the 4.5-hour time window for treatment are strongly desired in clinical practice, and we may achieve such goals by utilizing RTU-009 as combinationwith t-PA treatment. In addition, it wasrecently reported that removingthe thrombus intreatable patients within 6 hours of stroke onset via endovascular treatment (mechanical thrombus collection therapy or endovascular thrombectomy) improves treatment results as compared with conventional treatments. Based on this report, we would like to also explore a new treatment utilizing RTU-009, which has&nbsp; an anti-inflammatory effect,in combination with endovascular treatment. </td></tr></table>comunica@vhir.org (VHIR)Wed, 10 Jun 2015 00:00:00 GMTVHIR researchers presented the results funded by the Marató of 2009 devoted to rare diseases (09/06/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=104&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0104\2015_0104_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On Monday afternoon, 20 research projects funded by La Marató 2009 devoted to rare diseases were presented in the 16th Symposium La Marató of TV3, at the Institut d’Estudis Catalans’ facilities. There were researchers from Vall d’Hebron, who had participated in three of the projects. Inhibition of the Notch’s pathway as a therapeutic target in rhabdomyosarcoma Dr. Soledad Gallego, member from the Translational Research in Child Cancer group headed this project, which had the objective of analyzing the effect of the inhibition of the Notch’s signalizing pathway in a murine model in order to identify new therapeutic targets for rhabdomyosarcoma, which is a malignant tumour of soft-tissues, such as the muscles, tendons or the connective tissue. Thanks to the help from La Marató they could demonstrate the anticancinogenic effect of the inhibitors of this signaling pathway and their potential application as a therapy for the rhabdomyosarcoma. These results will be validated in 2016 in a clinical trial using different types of inhibitors. Furthermore, they have described a new method to detect rhabdomyosarcoma’s cells in liquid biopsies that will help to identify patients with a unfavorable evolution to intensify their treatment. &nbsp;&nbsp; Development of nanomedicines for the enzymatic substitution in Fraby’s disease&nbsp; Dr. Simó Schwartz, coordinator of the Nanomedicine Centre at VHIR (CIBBIM), headed this project in which also participate researchers from Institut de Bioenginyeria de Catalunya, Faculty of Chemistry at Universitat de Barcelona, Hospital of Santa Creu and Sant Pau, Institut de Ciència de Materials de Barcelona and Institut de Biotecnologia i Biomedicina of the Universitat Autònoma de Barcelona. The aim of the study was to develop a new drug delivery system to improve the therapeutic efficacy of the enzymatic substitutive treatment in Fabry’s disease, which is produced for the accumulation of liposomal Gb3 lipid depositions.&nbsp;&nbsp;&nbsp;&nbsp; As a result of the project, they designed a new nanoconjugated on the basis of lipid unilamelar vesicles that transport the defective enzyme, called alpha-galactosidase, via a specific targeting system against the endothelial membrane receptors. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-decorati</td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Jun 2015 00:00:00 GMTDr. García Fontecha has been awarded for the best paper in 2013-2014 by the Catalan Society of Pediatrics (05/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=103&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0103\2015_0103_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. César Galo García Fontecha has been awarded for the best paper in 2013-2014 by the Catalan Society of Pediatrics for the article “Mistakes made in pediatric orthopedics”, published on the association magazine. The objective of the paper was to present the most common mistakes in the treatment of orthopedic problems during the childhood, from a point of view based on the evidence, to try to prevent unnecessary or harmful treatments. Among the most common mistakes he detected, there are:&nbsp; the unnecessary placement of templates on flat feet, placing apparatus to correct the deviation of the legs, unfounded treatments like babies using two diapers to correct a congenital hip dislocation, or beliefs that suggest high weights in backpacks produces scoliosis. All these mistakes and how to correct them are available on the Society website. Dr. Fontecha told us: “the award has a special value for me because it means recognition to my teaching ongoing job in this field from specialists in pediatrics”. The award was given at the ceremony of the Academy Awards 2015, which took place in the auditorium of the Academy. </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Jun 2015 00:00:00 GMTThe Diabetes and Metabolism research group was awarded for its trajectory (03/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=101&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0101\2015_0101_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Endocrinology and Nutrition Spanish Society has rewarded the Diabetes and Metabolism research group from the Vall d’Hebron Research Institute (VHIR) with the FEEN award for their trajectory. The group, headed by Dr. Rafael Simó received the prize at the Society’s Annual Convention’s closing ceremony, on the 29th of May in Madrid. Dr. Rafael Simó has been coordinating the research in the field of diabetes and metabolism at VHIR since 1995. His group is investigating the pathogenesis and treatment of common diseases like diabetes and obesity. The team consists of basic and clinical researchers, and that produces relevant results and a very fast transmission of these results to the clinical practice. In the last 5 years, the research group has published 92 articles with an acumulate impact factor of 598 and 6.5 in average. Nowadays the group is coordinating the European consortium Eurocondor and is part of the Spanish work web CIBERDEM, specialized in diabetes and metabolic related diseases, and the national consortium RECAVA, formed by experts in cardiovascular diseases.&nbsp; The prize, funded by GSK, consists in 9,000 Euros and has the objective of awarding a national group, centre, service or department that has developed an excellent activity in the health care, the research or the teaching in the field of the nutrition and the endocrinology. </td></tr></table>comunica@vhir.org (VHIR)Wed, 3 Jun 2015 00:00:00 GMTThe 3rd DiR-Guàrdia Urbana race raises 3,500 euros for research in child cancer (02/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=99&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third edition of the DiR-Guàrdia Urbana race raised 3,500 euros for research in child cancer at Vall d’Hebron Institute of Research (VHIR). Nearly 8,000 people ran the entire Diagonal of Barcelona with two messages: “for you maybe is just a race, but for them is their life” and “run and help us to investigate for children with cancer”. The donation will fund the research carried out by the group headed by Dr. Josep Sánchez de Toledo, who after the race thanked the participants for their support and said that “if research stops, the world stops”. The 10km race was organized by VHIR with the collaboration of the Guàrdia Urbana and the Barcelona city council to promote exercise and healthy habits and to support a solidarity cause. In this case, they decided to support the research group led by Dr. Sánchez de Toledo, whose mission is to improve the diagnosis and treatments available for cancer during childhood. Each year in Spain nearly 1,000 children are diagnosed with child cancer and the survival rate is in the 80%. The Translational Research in Child and Adolescent Cancer group works closely with the Oncohematology Service at Vall d’Hebron University Hospital that is a reference international center in the treatment of cancer and hematologic diseases during childhood. Thanks to their experience, human resources and technological equipment, they offer a multidisciplinary attention to patients and relatives, covering all the diagnostic procedures and the most advanced treatments. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Jun 2015 00:00:00 GMTVHIR participates in a €3.9 million initiative to uncover biology of ADHD and autism (02/06/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=100&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0100\2015_0100_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Psychiatry, Mental Health and Addictions group at Vall d’Hebron Institute of Research (VHIR) participate in a major new initiative with the aim to uncover the biology of Attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). The project is unique in its kind through combining an interdisciplinary pan-European team of scientists and 15 PhD students, as well as cross-sectoral collaboration with industry. One of these PhD students will start to work at VHIR, in the ADHD research line, led by Drs. Josep Antoni Ramos-Quiroga and Marta Ribases. Funded by a €3.9 million grant from the EU Horizon 2020 Marie Sklodowska-Curie Training Network grant, the project, called MiND (Mastering skills in the training Network for attention deficit hyperactivity and autism spectrum Disorders), is believed to make major advancements to understanding the risk factors involved in the development of ADHD and ASD. It will also translate findings to offer individuals better diagnosis and more individualised treatment. The project involves 21 consortium members from 10 countries. ADHD and ASD are chronic and highly heritable neurodevelopmental disorders. ADHD affects around 5.3% of children and 2.5% of adults. ASD affects around 1% of children and adults. Despite their societal importance, progress in understanding their disorder biology has been slow and insufficient treatment options are available. The study MiND aims to tackle such shortcomings. On February, MiND beneficiaries successfully kicked off their 4-year project in a two-day meeting in Barcelona in the presence of representatives of the patient organisations ADHD-Europe and Autism-Europe as well as the EU program officers. Presentations by work package leaders and the EU officers were alternated with fruitful discussions in smaller groups. </td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Jun 2015 00:00:00 GMTIndustex employees visit VHIR to see the results of their donation (29/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=98&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0098\2015_0098_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Employees from the Catalan company of innovative products, Industex, returned to Vall d’Hebron Institute of Research (VHIR) in order to see the results of the 50,000 euros donation that co-funded in 2012 the first INCOMED call. The staff visited the lab of Dr. Rosanna Paciucci, researcher from the Translational Biomedical Research in Urology Group. In this lab also works Dr. Carlos Fernández, who received the INCOMED grant thanks to Industex. In Dr. Paciucci’s lab, they investigate prostate cancer, which is the most frequent cancer in men in western Countries and the second leading cause of death for cancer in Europe. The advanced metastatic cancer is still a major unresolved problem. In their lab, they have investigated the actions of the oncogenic protein prostate tumor overexpressed-1, PTOV1, that they discovered for its high expression in aggressive tumors and significantly associated with poor prognosis in prostate, breast, bladder, ovary and liver cancers. They have recently described two mechanisms of action for this protein that are implicated in prostate cancer progression. Thanks to the collaboration with Industex, they have discovered an additional action for this protein that is linked to its ability to repress a major tumor suppressor gene. These results further confirm PTOV1 as a significant target for future, more specific therapies in metastatic prostate cancer. Industex employees also visited VHIR in 2013.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 29 May 2015 00:00:00 GMTPROSICS and Interarts launch Diverxual, a platform of resources for sexual and reproductive health (28/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=97&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0097\2015_0097_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The project Decides España, developed by the International Health Programme of the Catalan Institute of Health (PROSICS) and Interarts, with the participation of Dr. Jordi Gómez, from the infectious diseases group at VHIR, has launched the webpage Diverxual, with the aim to provide to health professionals the knowledge and practical tools related with sexual and reproductive health. The platform offers specialized workshops, training videos, guidelines and official health protocols related to this field. The website is addressed to professionals working in public and private associations or entities who give support to immigrants in the access to sexual and reproductive health. Diverxual is part of the project Decides España, whose aim is to improve equity in the access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. PROSICS professionals did an assessment of the situation in Spain, which concluded that it was necessary to develop new educational and informative materials on affective sexual and reproductive health integrating the approach of equity, gender and cultural specificities. Decides España is project co-funded by the Financial Mechanism of the European Economic Area which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Active Citizenship Programme endowed with EUR 4.6 million to support the contribution of NGOs to social justice and sustainable development. You can follow the Active Citizenship Programme on Facebook and Twitter. </td></tr></table>comunica@vhir.org (VHIR)Thu, 28 May 2015 00:00:00 GMTVHIR trains science teachers in hepatitis B and C virus (27/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=96&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0096\2015_0096_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> 10 science teachers from several Catalan high-schools participated in the course “The hepatitis B and C virus: prevention, knowledge and innovations in the treatments”, organized by doctors Josep Quer and Francisco Rodríguez-Frías, researchers from the Hepatic Diseases at Vall d’Hebron Institute of Research (VHIR), in the framework of the Teachers and Science programme by the Catalunya La Pedrera Foundation. The duration of the course was 12 hours in which researchers introduced the main concepts of virology: which is the vital cycle of the virus, the routes of transmission, the risk of infection depending on the habits, the new methods of study based on massive sequencing techniques and the latest advances on research in this field. Besides the theory, Dr. Quer presented to them two educational games, that he designed together with the Spanish Society of Virology, in order to translate to the schools the knowledge about these virus: one of the games is called Virópolis, and it is available online, and the other one, Epidemia vir(TU)al, will be available soon as a mobile app. Teachers also visited the clinical labs of Vall d’Hebron University Hospital, where everyday nearly 6,000 blood samples from all Barcelona are analyzed. Nowadays, more than half of the deaths by infections worldwide are caused by the hepatitis virus, specifically the type C. The climate change and the aggressions to the ecology, as well as the geographical location of Spain put us in a zone of risk of viral emerging or re-emerging diseases. According to the World Health Organization, viral diseases are the cause of 2/3 of the medical consultations by infectious processes. </td></tr></table>comunica@vhir.org (VHIR)Wed, 27 May 2015 00:00:00 GMTThe 3rd DiR-Guàrdia Urbana race will raise funds for research in child cancer (26/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=22&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0022\2015_0022_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third edition of the DiR-Guàrdia Urbana race will take place in the Avinguda Diagonal, in Barcelona, on May 31st. Participants will run 10km of the entire Diagonal, with two messages: “for you maybe is just a race, but for them is their life” and “run and help us to investigate for children with cancer”. Part of the funds collected in the race will be donated to the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). The race will start at 8.30 AM at Palau Reial and the finish line will be located at Passeig Garcia Faria. Registrations are already open on www.dir.cat and in any of the gyms of the group. The mission of the Translational Research in Child Cancer group is to improve the diagnosis and treatments available for these diseases. </td></tr></table>comunica@vhir.org (VHIR)Tue, 26 May 2015 00:00:00 GMTVHIR participates in two studies that could change the surgical protocols of hip fractures in the elderly (25/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=93&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0093\2015_0093_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Reconstructive Surgery of the Locomotor System group at Vall d’Hebron Institute of Research (VHIR), led by Dr. César Galo García-Fontecha, and the Traumatic Unit of the Traumatology Area at Vall d’Hebron University Hospital, headed by Dr. Vicente Molero, participate in two ongoing studies that could change the surgical protocols of hip fractures in the elderly. The studies are multicenter, prospective and randomized, and coordinated by Dr. Mohit Bhandari, from the McMaster University in Ontario, Canada. According to Dr. García-Fontecha, “both studies could mark a milestone for the orthopedics community, because they will probably change the treatment of fragile old people with comorbidities that suffer hip fractures”.&nbsp; Nowadays, between the 20 and 30 per cent of patients with hip fractures die during the first year. In addition, hip fractures are associated to a high risk of complications, re-operations and disability. The first study, called HeEALTH and led by Ernesto Guerra and Jordi Teixidor, compares the outcomes of the bipolar prosthesis versus total prosthesis in femoral neck fractures. The objectives of the project are to improve the functional results and avoid complications and reoperations. On the other side, the Hip Attack study, led by Ernesto Guerra and Jordi Tomàs, examines whether 'accelerated' surgery (carried out in the first 6 hours after the diagnosis) results in better recovery, better outcomes, and less deaths, when compared to current practice (currently, most people have surgery within 48-72 hours). However, if accelerated surgery is shown to be better, as it happened in the pilot study, Dr. Guerra says that “this could entirely change the way hip fracture patients are treated, because we will have to do codes of procedures such as the Stroke Code or the Myocardial Infarction Code, in which a fast intervention is essential for saving lives”.&nbsp;&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Mon, 25 May 2015 00:00:00 GMTMore than 2,000 people celebrated the 20th birthday of the research at Vall d'Hebron with a solidarity party (23/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=79&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0079\2015_0079_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On Saturday we celebrated the Party of the Research at Vall d’Hebron, at the Pavelló Olímpics Vall d’Hebron, the first organized by a research institute of a hospital in Catalonia, where more than 2,000 people attended. The popular celebration closed the 20th anniversary of the Vall d’Hebron Research Institute (VHIR) and was the preamble of the 60th birthday of the University Hospital Vall d’Hebron. The objective of the party was to make people aware of the importance of research and also to connect the society with the best biomedical research. The celebration was promoted by Andrés Iniesta, VHIR’s ambassador, Tomàs Molina, who participated as a Friend of VHIR, and Judit Mascó, and was possible thanks to La Caixa, Sanofi and Palex. From 10am to 12:30am and from 3pm to 5pm in the Sala de la Recerca inside the Pavelló, VHIR’s researchers offered scientific workshops and showed the best scientific photographs from the photo competition we do every year. Furthermore, everybody could see what the most important research lines in the Hospital are, looking at the posters we put on the walls. The first people that came, at 10am, found some chocolate to drink outside the Pavelló. Then, from 10.30am to 12.30am they enjoyed the Radio Flaixbac’s DJ’s workshop, with Andreu Presas, and also a </td></tr></table>comunica@vhir.org (VHIR)Sat, 23 May 2015 00:00:00 GMTRaimon performed at the Teatre Principal d'Olot to raise funds for the research in VHIR (19/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=91&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0091\2015_0091_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Last Friday, the 8th of May, the singer-songwriter Raimon made a solidarity concert at the Teatre Principal d’Olot to inaugurate his tour. The concert, wich was organized by the Albert Bosch Foundation, was a success and the tickets sold-out. The money collected will be destined for the research projects of the group “Translational Research in Child Cancer” at Vall d’Hebron Research Institute (VHIR). He played old songs like ‘Diguem no’ or ‘Com un puny’, but new ones too. He also singed poems from Ausiàs March, Roís de Corella, Jaume Roig o Salvador Espriu. The concert was so special because he hadn’t performed in Olot for 20 years. The money collected will impulse the research group headed by Dr. Sánchez de Toledo. From VHIR we want to thank the Albert Bosch Foundation, who has collaborated many times with us, for the initiative. </td></tr></table>comunica@vhir.org (VHIR)Tue, 19 May 2015 00:00:00 GMTVHIR celebrates the first scientific retreat to talk about the science made at Vall d'Hebron (15/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=90&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0090\2015_0090_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Prullans, in la Cerdanya, hold of the first scientific retreat of the Vall d’Hebron Institut de Recerca (VHIR). In the meeting participated group leaders, principal investigators, young researchers and the heads of the VHIR's structural units, with the aim to discuss the present and the future of the research in the Institute and the outlines of the new strategic plan for the period 2016-2020. During the meeting, 15 research groups presented their research lines and landmarks, in order to disseminate their work, facilitate the interactions and share common lines. The second day began with a speaking about the VHIR’s strategic positioning and the research transversal programs that will be implemented in the future. Among these programs, three were presented: the Nanomedicine and Advanced Therapies Centre, headed by Dr Simó Schwartz, the Spina Bifida Program, coordinated by Dr. Elena Carreras, and the Translational Immunology and Systems, headed by Dr. Ricard Pujol. All the researchers also participated in several focus groups to discuss the main points to take into account to prepare the Institute’s strategic plan for the next five years. Retreat pictures </td></tr></table>comunica@vhir.org (VHIR)Fri, 15 May 2015 00:00:00 GMTVall d'Hebron clausura las XIII Jornadas Anuales del Síndrome de Fatiga Crónica (14/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=89&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0089\2015_0089_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Por treceavo año consecutivo se han celebrado, los días 13 y 14 de Mayo de 2015, la Jornada del Síndrome de fatiga crónica en el salón de actos del Pabellón Docente del Hospital Universitario Vall d'Hebron de Barcelona, coordinada por el Dr. José Alegre, jefe del grupo de investigación de esta enfermedad en el Vall d’Hebron Institut de Recerca (VHIR). La jornada, considerada de referencia a nivel nacional, ha contado con especialistas de primer nivel que han expuesto los temas más relevantes en relación con este complejo síndrome que comporta una importante limitación funcional, tanto en las actividades de predominio físico como intelectual, en forma de incapacidad laboral en el adulto y fracaso escolar en el niño. En el momento actual se están dando pasos de gigante en el cocimiento de la severidad de la fatiga crónica en todo su contexto. Esto es posible gracias a la ayuda de las nuevas tecnologías y la inclusión de grupos de trabajo multidisciplinares de biotecnólogos, ingenieros y matématicos que utilizan programas informáticos utilizando dispositivos móviles, estudios de neuroimagen, fisiológicos y de citometría de flujo funcional. El eje central de las jornadas científicas se ha centrado en los avances en el estudio de la disfunción del sistema nervioso autónomo en el síndrome de fatiga crónica, con la utilización de elementos de medida no agresivos, y la introducción de programas informáticos en los dispositivos móviles. El estudio lo lideran diversos investigadores clínicos y  básicos del VHIR, y profesionales del Instituto Catalán de Farmacología, la Universitat Autonòma de Barcelona, la Universidad Politécnica de Cataluña, la Fundación Futbol Club Barcelona y la empresa Health &amp; Sportlab. Por otro lado, en las jornadas se han comentado aspectos relevantes de la valoración de la severidad de la intolerancia al ejercicio físico en esta enfermedad, con técnicas ergométricas y de biología molecular. También se han presentado las aportaciones de la neuroimagen y la neurobiologia en el estudio de la disfunción cognitiva, la importancia de la investigación del fenotipado linfoide en la valoración de la disfunción inmune y el estudio de los fenómenos asociados, tales como el mayor riesgo de síndrome metabólico y del desarrollo posterior de neoplasias. Entre medio de las dos sesiones, se presentó  la Asociación Dolfa, la primera asociación en España para fomentar la investigación clínica y básica en el síndrome de fatiga crónica en niños y adolescentes. La jornada ha culminado con un seminario a cargo de la Dra. Zoe M. Gotts, investigadora postdoctoral del Newcastle Fatigue Research Center, del Reino Unido. Gotts es una autoridad europea en este campo, y está especializada en el impacto de la disfunción del sueño en la fatiga crónica. </td></tr></table>comunica@vhir.org (VHIR)Thu, 14 May 2015 00:00:00 GMT El Dr. Josep Sánchez de Toledo rep la Medalla Josep Trueta en reconeixement a la seva tasca per al progrés i millora de la sanitat (13/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=88&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0088\2015_0088_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> El Dr. Josep Sánchez de Toledo, cap del grup de Recerca Translacional en el Càncer a la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR) i cap del Servei d’Oncologia i Hematologia Pediàtrica de l’Hospital Maternoinfantil Vall d’Hebron, ha rebut aquest dimarts la Medalla Josep Trueta al mèrit sanitari en un acte al Palau de la Generalitat. Sánchez de Toledo ha estat una de les 13 figures de la sanitat catalana que han vist reconeguda aquest vespre la seva tasca i els serveis prestats amb vista al progrés i la millora de la sanitat. Llicenciat en medicina i cirurgia a la Universitat Autònoma de Barcelona l’any 1974, el Dr. Sánchez de Toledo és especialista en Pediatria i un dels pioners en el desenvolupament de l’assistència i la recerca en el càncer a la infància. Ha estat president de la Sociedad Española de Oncología Pediátrica i de la seva fundació. Va impulsar la creació del Registre Nacional de Càncer Infantil i del registre català. El Dr. Josep Sánchez de Toledo combina el seu treball clínic en infants amb tumors i trasplantaments de medul·la òssia amb la més avançada recerca en càncer infantil. Actualment, a més de ser cap del seu grup, és membre del Consell Científic Intern del VHIR. També forma part del Comitè Científic de l’Associació Espanyola Contra el Càncer a Catalunya (AECC) i és el president del Comitè Científic de la Federació Oncològica de Catalunya. És membre de diverses societats científiques nacionals i internacionals i presideix la Comissió de Tumors de l’Hospital Vall d’Hebron i de la Comissió Assessora del Pla director d’oncologia de Catalunya. L’any 2012 va rebre el Premi a l’Excel·lència Professional del Col·legi de Metges de Barcelona i el 2013 va ser guardonat com a Català de l’Any 2012, premi que atorguen El Periódico de Catalunya i Televisió de Catalunya. El Servei d’Oncologia i Hematologia Pediàtrica de l’Hospital és capdavanter en el desenvolupament dels trasplantaments de progenitors hematopoètics en nens. L’any 2012 va obtenir l’acreditació internacional JACIE, que distingeix la qualitat assistencial, i l’any 2013 el premi Best in Class al millor servei d’Oncologia de l’Estat i l’any següent el Best in Class al millor servei de Trasplantaments. </td></tr></table>comunica@vhir.org (VHIR)Wed, 13 May 2015 00:00:00 GMTÉxito de las VIII Jornadas de Salud Internacional (12/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=87&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0087\2015_0087_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Más de 160 profesionales participaron en las VIII Jornadas de Salud Internacional celebradas en Barcelona del 7 al 8 de mayo y organizadas por investigadores y médicos del Vall d'Hebron y el Programa de Salud Internacional del Institut Català de la Salut (PROSICS). Durante dos días pudieron compartir información actualizada sobre vacunaciones y otros temas de interés sobre la especialización en salud internacional. Más concretamente, los profesionales hablaron sobre las novedades en vacunas para la enfermedad del ébola y el VIH o el dengue, los últimos brotes que han habido, y la importancia de la salud comunitaria en personas inmigradas, entre otras cuestiones. Anualmente, las unidades de salud internacional del ICS realizan unas 30.000 visitas de atención al viajero y dispensan más de 60.000 vacunas. El grupo de Enfermedades Infecciosas del VHIR, liderado por el Dr. Benito Almirante, está especializado en patologías internacionales como el Chagas, la malaria y la tuberculosis. </td></tr></table>comunica@vhir.org (VHIR)Tue, 12 May 2015 00:00:00 GMTResearchers identify a mechanism involved in the resistance to antitumor treatment (11/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=84&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0084\2015_0084_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Molecular Pathology group at Vall d’Hebron Research Institute (VHIR), headed by Dr. Santiago Ramon y Cajal, have discovered that the phosphorylation of a protein, elF4E, confers resistance to cell stress, including the treatments that damage DNA, like cisplatin. The results of the study have been published in PLOS ONE. After a decade studying the signaling factors in in vitro models, researchers observed that high levels of 4EBP1 and EIF4E phosphorylated are associated with more aggressive tumors and a worse prognostic. Seeing these unexpected results, researchers from VHIR decided to start this study to analyze the role of the elF4E phospholylation and its implication in the resistance to agents that produce cell stress, like gene damage. With the collaboration of Dr Nahum Sonenberg’s group, from the University of McGill in Montreal (Canada), VHIR’s team carried out in vitro and murine models with several molecular approaches. With these models, as Dr Ramon y Cajal said “we have seen that blocking the elF4E phosphorylation, genetically or with chemical inhibitors, we cells become more sensitive to the classic treatment with chemotherapy”.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With these results, the study’s lead author says that the door to optimize the standard chemotherapy treatment has been opened: “if we combine the chemotherapy of cytotoxic agents (like cisplatin) with selective inhibitors of these kinases, that don’t have relevant side effects, patients will suffer fewer side effects”. Additionally, the cytotoxic dose will be reduced and therapeutic effect increased. At present, there are two types of treatments available to fight against tumor cells: the cytotoxic treatments, which have a powerful antitumor effect but present many side effects, and the treatments with specific inhibitors for punctual genetic alterations, which are very selective and have fewer side effects. Nevertheless, tumor cells have many molecular alterations, and tumors usually become resistant to the specific inhibitors therapy. Now, together with the Organic Chemistry group from the Instituto Químico de Sarrià, VHIR researchers are trying to find new MNK kinase inhibitors, which would be more selective and effective, in order to potentiate the antitumor effect of the chemotherapy treatment with cytotoxic agents. </td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTResolution of the 20 finalist projects of the VHIR's Innovation Contest in Health (11/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=85&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0085\2015_0085_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Knowledge Transfer and Innovation Unit has just published the list of the 20 finalists of the VHIR’s Innovation Contest. Projects from biomedical research studies: - Gene Therapy for MNGIE using a new orphan drug consisting of an adeno-associated vector carrying TYMP. Vall d’Hebron Institut de Recerca (VHIR). - Pushing Myc inhibition to the clinic using cell penetrating peptides. Vall d’Hebron Institut d’Oncologia (VHIO). - Desarrollo de un kit de biomarcadores mitocondriales en sangre para el diagnóstico precoz del Alzheimer. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). - Desarrollo de un Chip Microfluídico para la Detección Precoz de Malaria. Vall d’Hebron Institut de Recerca (VHIR). - Detecció de la Neuropilina-1 (NRP-1) en l'orina com a biomarcador de pronòstic en la nefritis lúpica. Vall d’Hebron Institut de Recerca (VHIR) y Centro Superior de Investigaciones Científicas (CSIC). - Cardiopatch: Bio-Pegats digitals per al seguiment dels nounats amb cardiopaties. Vall d’Hebron Institut de Recerca (VHIR) y Centro Superior de Investigaciones Científicas (CSIC). - Ús d’un mètode per al mesurament d'ApoJ-Glicosilada per a la detecció precoç i l’estratificació de pacients amb infart agut de miocardi. Hospital de Sant Pau e Institut Català de Ciències Cardiovasculars (ICCC). - CeliFast, Rapid diagnosis of celiac disease at point of care based on magneto platforms. Hospital Germans Trias i Pujol. <p style=" text-align: left; text-indent</td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTVHIR participates in activities for the International Fibromyalgia and Chronic Fatigue Syndrome Awareness Day (11/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=86&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0086\2015_0086_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 12th of May, has been designated as the International Fibromyalgia and Chronic Fatigue Syndrome/Encephalomyelitis Myalgic (CFS/ME) Awareness Day. The Chronic Fatigue Research Group at Vall d’Hebron Research Institute (VHIR), led by Dr José Alegre, is organizing a series of events in order to raise funds for CFS/ME research. With the same objective, the Foundation of patients affected by Fibromyalgia and CFS/ME and the IrsiCaixa Foundation have prepared a fundraising auction that will take place this Tuesday at 5:30 PM at the Pedrera’s Auditorium in Barcelona. 2015 CFS/ME Advances Day  Dr José Alegre coordinates again these sessions that will be held on the 13th of May at the Pabelló Docent Auditorium at the Vall d’Hebron Hospital, from 11 AM to 7 PM. The sessions are aimed to professionals, administration, associations and foundations of patients affected by Fibromyalgia, CFS/ME and Multiple Chemical Sensitivity, and have the objective to insight into the last advances in these conditions. The topics that will be discussed are research on exercise intolerance, study of the autonomic dysfunction and the impact of the comorbidity in the CFS/ME. VHIR’s Seminar Dr. Zoe M. Gotts, of the Newcastle Fatigue Research Centre, U.K. will present the seminar “Sleeping through fatigue”, on the 14th of May at 3:30 PM in the Conference Room on the ground floor at the General Area of Vall d’Hebron Hospital. The researcher will share last research in sleeping disorders in CFS/ME patients, which her group has been carrying out in recent years. Charity Concert La Contemporània will celebrate its 20th birthday on the 14th of May at 9PM doing a charity concert in the Pabelló Docent at Vall d’Hebron Hospital. The concert, called “Vint Tocats”, will go over the copla’s history, presenting funny proposals.&nbsp; The tickets will be offered for sale the same day in the place of the concert, and will cost 10 Euros. It is recommended not wearing any kind of cologne or perfumes to respect patients affected by multiple chemical sensitivity. Charity Art Auction <span style=" font-size: 8pt; font-family: 'Verdan</td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTThe Research Group on Neuromuscular and Mitochondrial Diseases is investigating to improve Antonio's quality of life (08/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=82&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0082\2015_0082_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Antonio is a three-year-old child who has a rare disease called mitochondrial myopathy due to thymidine kinase 2 (TK2) deficiency. This is a genetic disease that affects very few people in the world. The Research Group on Neuromuscular and Mitochondrial Diseases of VHIR, which studies and seeks for new treatments for this and other related diseases, made the genetic diagnose of Antonio and is helping to better understand the illness in order to improve the quality of life of these patients. The disease that Antonio suffers is caused by a genetic defect leading to protein TK2 deficiency. This protein is very important because is responsible for producing and maintaining the DNA from mitochondria, which are the intracellular elements providing energy to the cell, among other important roles. As a consequence of TK2 deficiency, patients are lacking two of the nucleotides that form the mitochondrial DNA, which affects several organs of the patients. Specifically, patients have problems in the function and development of their muscles, and their mobility and respiratory function can be compromised. For the moment, only one expensive treatment has been proposed to improve the quality of life of these patients. This treatment is based on the administration of the missing nucleotides. But now, the Research Group on Neuromuscular and Mitochondrial Diseases of VHIR, with Dr Ramon Martí as principal investigator, has suggested an alternative therapy, which is cheaper than the other, and is based on the administration of the nucleotides’ precursors: the nucleosides. As the doctor said: "up to now, the experimental facts indicate this alternative treatment is as efficient as the previous one". Importantly, production of nucleosides is significantly cheaper, which would help assuring all patients get access to the therapy. Antonio is trying this new therapy and, so far, results are as good as expected. Antonio’s parents have developed a platform with a website to raise awareness of the disease and to collect money to guarantee Antonio’s treatment and to fund research on the disease. Before long, on the 30th of May, they are going to inaugurate a solidarity photograph exhibition in order to raise funds to support the investigation carried out by the Research Group on Neuromuscular and Mitochondrial Diseases. These resources are going to be invested in the research on this disease and to develop therapeutic approaches to improve the quality of life of Antonio and all other patients suffering from TK2 deficiency.&nbsp;&nbsp; This is the exhibition's poster. </td></tr></table>comunica@vhir.org (VHIR)Fri, 8 May 2015 00:00:00 GMTGinger bread signature chocolate to fight against ovarian cancer (07/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=81&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0081\2015_0081_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> To celebrate the Ovarian Cancer World Day, on the 8th of May, the Gynecology Service in Vall d’Hebron University Hospital and the Biomedical research group in Vall d’Hebron Research Institute (VHIR) have started a campaign to raise awareness of the disease in a different way. For that reason, and seeing the last year’s success, they have the collaboration of Daniel Jordà (Panes Creativos) and Oriol Balaguer, who have recuperate the traditional bread and chocolate with a solidarity objective: sell it with a symbolic prize (2 Euros) to raise awareness of the disease and fundraise for the research. Both bakery artists from Barcelona have created, specifically, for the Ovarian Cancer World Day a piece of bread made off ginger and chocolate, two helpful ingredients to prevent this kind of cancer. The bread has been created using equilibrated ingredients by Daniel Jordà, who was inspirited in the Frances brioche. The chocolate, made by Oriol Balaguer has a vanilla taste and a soft texture. The creation will be sold the 8th of May in the Arcasa cafes of the Vall d’Hebron Hospital, in both establishments of the authors, in the Boqueria Market and in the BCNandCAKE shops that are attached to the campaign. A part from the bread and chocolate, solidarity bracelets are offered for sale to collect money for the research. These bracelets have been created by&nbsp; Samburu Accessoriesfor the occasion and can be purchased for 5 Euros. On the 8th of May, there are going to be different informative points in the halls of the Maternal and Child area and the General area of the Hospital Vall d’Hebron. The researchers from VHIR and from the Gynecology Service of the Hospital are going to do the awareness campaign, with the collaboration of the Asociación de Afectados por Cáncer de Ovario (ASACO). They are going to give stickers with the slogan of the campaign: “Una voz por todas”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 7 May 2015 00:00:00 GMTVall d'Hebron shows to the industry the innovation carried out by Catalan hospitals and research centers (05/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=80&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0080\2015_0080_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> In the Catalan hospitals and research centers there are a lot of innovative ideas, but frequently don’t go any further just because their professionals are not trained in techniques of knowledge transfer. This is the point that defends the responsible of the Knowledge Transfer and Innovation Unit at Vall d’Hebron Institute of Research (VHIR), Raquel Egea, in order to explain why the knowledge transfer is still poor among the Catalan hospitals and biomedical research centers, compared to other sectors and regions. According to the data provided by the Spanish organization of patents and brands (OEPM), the applications for patents decreased by 30% in Catalonia in the last 7 years and positions the region behind others such as Madrid and Andalusia. However, if you take a look at the bibliometric indicators, Catalonia is leader in terms of visibility, excellence and cooperation in the field of biomedical research, according to a study by the Research Group on Bibliometrics. With the aim to encourage health professionals to turn their ideas into solutions, VHIR opened to all Catalan research centers and hospitals the 2nd edition of the Innovation Contest in Health. And the response was very positive because among the applicants, there are projects from Hospital Clínic, Hospital de Bellvitge, Hospital de Sant Pau, Hospital Germans Trias i Pujol, Hospital Josep Trueta, Hospital Joan XXIII, Hospital Parc Taulí, Vall d’Hebron Institut d’Oncologia (VHIO), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), l’Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), IDIAP Jordi Gol and Institut de Recerca Biomèdica de Lleida (IRB Lleida). According to the responsible of innovation at VHIR, “the high number of applications is a success that demonstrates that hospitals and biomedical research centers have a large potential in innovation”. Now all the projects submitted are being evaluated and on May 11 will be published the finalists that will receive training in the field of knowledge transfer and innovation. Specifically, finalists will receive lessons to write a feasibility report, to know the details of the valuation process and the possibilities of funding for their projects. This training will be carried out by experts from Connecting Perspectives, Inveready, Trifermed and Barcelona Institut d’Emprenedoria. In addition, each participant will have tuition by an expert in innovation. <p style=" tex</td></tr></table>comunica@vhir.org (VHIR)Tue, 5 May 2015 00:00:00 GMTStudy identifies a key factor in the neural death that causes Parkinson's disease (29/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=77&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0077\2015_0077_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> In studying the molecular biology of brain development, a team of researchers from the Ludwig Cancer Research in Stockholm has discovered how disruption of a developmental mechanism alters the very nerve cells that are most affected in Parkinson’s disease. They have also explained how such disruption induces a lethal dysfunction in the internal, house-keeping processes of such neurons. The results of their study, in which the co-corresponding author is Dr. Ariadna Laguna, from the Neurodegenerative Diseases group at Vall d’Hebron Institute of Research (VHIR), are published in the current issue of the journal Nature Neuroscience. The study took nearly four years to complete and involved the exquisitely targeted manipulation of mouse genes to generate a unique model of the disease. According to the Ludwig Stockholm director, Thomas Perlmann, “the model, in many important ways, mimics the manifestation of Parkinson’s in humans and has illuminated what appears to be a key mechanism of neural decline in this devastating disease”. Dr. Ariadna Laguna participated in this study during her postdoctoral fellowship at the Ludwig Cancer Research. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Apr 2015 00:00:00 GMTSurgery improves survival of women over age 80 with breast cancer (28/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=76&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0076\2015_0076_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Research Unit in Biomedicine and Translational Research in Gynecology and the Gynecological Service of the Vall d’Hebron University Hospital, led by Dr. Antonio Gil, have demonstrated that surgery is the best option to treat women over 80 years with breast cancer in early stages (I and II). The conclusion, published in the European Journal of Surgical Oncology, was obtained after comparing the evolution of 465 women with breast cancer treated in Vall d’Hebron between 1995 and 2012.&nbsp;&nbsp; Nearly the 30% of women diagnosed with breast cancer are over 80 years old and have, in most of the cases, hormonal tumors. In this situation, oncologists have two options: to operate them in order to remove the tumor, to add radiotherapy or chemotherapy and to give hormone treatment (if it’s necessary); or to administrate a primary endocrine treatment without surgery. One of the principal authors of the study, who is an associate doctor of the Gynecology Service and the Centre of Breast Cancer in Vall d’Hebron, Dr. Tomás Cortadellas, said: “physicians sometimes choose hormone therapy, the less aggressive option, just to avoid the side effects of the surgery standard treatment". Hormone therapy blocks the hormones and stops the tumor growth, but only for a few years. Specifically, researchers have shown that patients treated with hormone therapy in Vall d’Hebron presented an average of 50 months survival, while the operated women lived 109 months after the diagnosis. Besides the survival analysis in both groups, researchers observed that, in the operated group, some of them received a less aggressive surgery with suboptimal oncology results. This clinical decision neither help the patients: the ones who received an optimal surgery treatment (removal of the tumor, the sentinel node and other nodes, if it’s necessary) lived, on average, two years and a half more than the ones who received a minor surgery. At the time of doing the comparative analysis of both groups, Dr. Cortadellas studied patient’s comorbidity (that is to say, the diseases or health problems that patients also presented) to determine if their state of health could influence the treatment they received. To do this, he calculated the Charlson comorbidity index, which evaluates the patient’s life expectancy in the next 10 years. The results were homogeneous: “all the patients included in the study presented the same comorbidity, so we can compare both treatments”, said the physician. A part from this index, in order to confirm the homogeneity of the groups, he also compared other parameters like the chemotherapy and radiotherapy dose they received, the lymphovascular invasion, the tumor stage or the expression of the gene HER2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The increase in longevity requires changing the treatment <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-se</td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Apr 2015 00:00:00 GMTVHIR showed at the BCN Science Festival the proteins hidden in the fruits (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=75&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0075\2015_0075_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> How many proteins are hidden in the fruits? This is the question that Miguel Aranda, researcher from the Kidney Physiopathology group at VHIR, asked to the visitors of the NOVUM Barcelona Science Festival. On Sunday morning, many children participated with their families in his workshop, located at the Plaça de les Glòries, in Barcelona, in order to know the role of the proteins in fruits and humans. The aim of Miguel’s workshop was to explain the role of proteins and why is useful to count them. In his lab, researchers study pathologies such as Dent’s disease that is characterized by the loss of proteins through the urine and leads to chronic kidney failure. The Barcelona Science Festival, which in the past editions was located at the Parc de la Ciutadella, was organized by the Barcelona city council with the aim to promote the activity carried out by research centers and scientific associations from the city. Read the poster of the workshop on this link. </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTThe second preinscription period for the 2nd edition of the Master's Degree in Translational Biomedical Research VHIR is finishing (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=27&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0027\2015_0027_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR), associated to the Universitat Autònoma de Barcelona, opens again the registrations of the 2nd edition of the Master’s Degree in Translational Biomedical Research UAB-VHIR, which will start on October 2015. The first preincription period finished with around fifty access requests and thirty-six pupils admitted. Due to the quantity of registrations demand, the Coordination Comission of the Master decided to expand the number of places offered to 50 for the course 2015-2016. The second preinscription period will be closed on the 15th of July and then the registrations will be evaluated. At the end of July, the name of the admitted pupils will be communicated. As a new feature of this year’s edition, students will have to choose three out of the six optional subjects, taught by researchers and clinicians currently working at Vall d’Hebron University Hospital. The optional subjects are: Brain and Nervous Peripheral System Diseases; Cardiovascular and Kidney Diseases; Oncology Diseases; Liver and Digestive Diseases; Microbiology, Infectious Diseases and Critical Pathology; and Respiratory, Immune, Systemic and Endocrine System Diseases. The program will also offer new lessons on transversal competences, such as communication and outreach, business development, national and international calls, and project management. The aim of the master is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. It is addressed to research career, providing access to a PhD program related to the biomedicine area that the students had previously chosen for their training program and internship. In this regard, the master is an excellent occasion for working in a biomedical research laboratory with first-rate scientists and clinicians. Registration process </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (24/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received this morning the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Apr 2015 00:00:00 GMTVHIR proposals for Sant Jordi (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=71&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0071\2015_0071_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Here you have our three recommendations for this Sant Jordi’s Day: ‘En Roc al Planeta Mascareta’, ‘Nano-Oncology, the Turning Point’ and ‘Aians’. These three books are written by professionals from Vall d’Hebron Hospital. En Roc al Planeta Mascareta Roc is a kid who after escaping from the paws of a terrible dragoon (the disease), with the help of his horse (his family), arrives to Mascareta Planet (the hospital), where he will live many adventures and many people will help him (clinicians, nurses, psicologists…). The adventures represent different phases of the disease. The authors of the book are two nurses of the Oncohematology Service, Raquel Moya and Carmen Biota, and the Acuna Patata association. The price of the tickets is 6 euros that will directly go to the research in Child Cancer at VHIR. You can buy the book on Sant Jordi’s Day from 9AM to 3.30PM in front of the maternal and child building. You can also buy it through the website of the association and by email to Dr. Miguel Segura. Nano-Oncology, the Turning Point “Far from the public perception that nanotechnology and nanomedicine are still trending topics of science fiction, a new emerging reality is deepening its roots in our society and people begins to realize that a new giant wave is going to smash our shores in the form of a technological revolution... and the impact might even go beyond imagination”, wrote Dr. Simó Schwartz, head of the CIBBIM-Nanomedicine, in the foreword of Prof. Victor Puntes’ book.&nbsp; Sharing his professional and personal experiences in the laboratory and the teaching, Dr. Puntes, who is currently working as a researcher in the CIBBIM-Nanomedicine area at VHIR, leads us in this fascinating revolution through the pages of his book. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTRecognition of the professional career of three researchers from VHIR (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=74&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0074\2015_0074_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr Josep Sánchez de Toledo, responsible of the group of Translational Research in Child Cancer in the Vall d’Hebron Research Institute (VHIR) and responsible of the Oncology and Child Haematology Service was awarded with the Medalla Josep Trueta. This recognition is given by the Generalitat de Catalunya with the objective of honoring professionals or entities that have stood out for the services rendered in view of progress and improving health. Dr Sánchez de Toledo combines his clinical work in children with tumors and bone marrow transplants with the most advanced research in childhood cancer. To recognize his intensive activity for the children welfare and his leading research, his research group collects donations from important entities, patients associations and citizen’s initiatives, and obtains European and Catalan competitive aids, like La Marató de TV3. New memberships of the Real Academia Médica Besides, two other researchers received also an important recognition for their work in health care and research. The Reial Acadèmia de Medicina de Catalunya designated corresponding academician the Dr. Ricard Pujol, responsible of the Immunology research group in VHIR, and Dr Santiago Ramón y Cajal, responsible of the Oncology and Pathology Molecular research group. Dr Pujol, nowadays, is combining his work in VHIR with being the responsible of the Immunology Service of the Hospital and is a research adviser of the Institut Català de la Salut (ICS). In the field of the research, professor Pujol is an international leader in the study of the autoimmune diseases, especially in the Graves disease, and either in the identification of new biomarkers to diagnose these illnesses. Dr Ramón y Cajal also shares his dedication in VHIR with being the responsible of the pathological Anatomy Service in the Hospital. In the research field, he is a pioneer in the study of the signaling pathways in human tumors, the study of the aging gene expression in tumors and the identification of therapeutic targets associated with the tumor progress and the pharmacological resistance in colorectal carcinomas. A part from this recognition, Dr Ramón y Cajal has been recently chosen member of the Real Academia Nacional de Medicina. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTCome to the Party of the Research at Vall d'Hebron (21/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=69&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0069\2015_0069_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Get it in your diary: Saturday 23rd of May, Pavelló Olímpics (in front of the University Hospital Vall d’Hebron). We have organized a lot of activities and surprises to celebrate with all the society our 20th birthday, and also as a preamble of the 60th birthday of our Hospital. This day you will see what kind of research we do in VHIR, through scientific workshops and an exhibition of amazing photographs (the winning images of the science photography competition). But especially it will be a feast day, with activities for all the family: bouncy castles, music, games for the children, dancing, magic, sports and a lot of solidarity. There will be sweepstakes, a big solidarity paella, merchandising and deep gratitude, because with these activities we want to make the society aware of the importance of the research and bring the opportunity to collaborate with the biomedical research in VHIR. The party will be amused by the Magician Andreu, the TV star Enric Company and the VHIR, our mascot! In the afternoon there will be the winning group of the last edition of the TV program Oh Happy Day!, that will perform on the Pavilion’s stage. But there will be more music: los Fugados de Alcatraz, who will sing together with the Choir of the Vall d’Hebron our song called ‘Aire’, written by Pedro Pardo and Marta Hernández, and the concerts of Manu Guix, Boxet, la Gira-sol and other special invitees. So, don’t think it twice. We want to see you on Saturday 23rd of May from 10h to 20h in the Pavelló Olímpics. You will have a nice day with surprises and discoveries! </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Apr 2015 00:00:00 GMTVall d'Hebron releases 250 balloons, one for each known primary immunodeficiency disease (20/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=66&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0066\2015_0066_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Research Institute (VHIR) is joining, one more year, the celebration of the World Primary Immunodeficiency Week, which has the objective of increase the recognition and the diagnosis of these diseases. This year 250 ballons have been released with the collaboration of the 5th course students of the School Jesuïtes de Sant Gervasi-Infant Jesús and with the support of Designa SCP. Children diagnosed with Primary Immunodeficiency Diseases (PID) in the Hospital have also participated, with their families and clinicians. Primary Immunodediciency Diseases (PID) PID is a group that includes more than 250 different rare or minority illness caused by alterations in the immunology system of the children. They affect one in every 2.000 live newborns, and these people are susceptible to suffer severity infections that, in case of not being treated properly, could be dangerous or cause lasting damage. The early diagnosis and the research to find more effective treatments are very important to assure the patients survival and to improve their quality of live, reducing the lasting damage. Nowadays PID isn’t a sanitary priority and neither social. PID in the Vall d’Hebron Hospital The University Hospital Vall d’Hebron leads the health attention of the pediatric patients in our country, with more than 700 diagnosed patients, the 70% of the total in Catalonia, according to the figures reported by the PID European Register of the European Society for Immunodeficiency and by the Jeffrey Modell Foundation (JMF). And among them, more than 400 are under 18 years old. In VHIR, the research groups of Infection in immunocompromised pediatric patients and Immunology investigate about it. <span style=" font</td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTVHIR has obtained the HR Excellence in Research recognition (20/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=68&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0068\2015_0068_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Research Institute (VHIR) has obtained the recognition of the European Commission HR Excellence in Research. This recognition proves that VHIR endorses the general principles of the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers (Charter &amp; Code), and firmly supports its commitment in improving internal policies and procedures. This recognition of excellence is an opportunity to establish a comprehensive and coherent Human Resources Strategy, that should allow to achieve international visibility. On March 2014, the VHIR initiated the process for the award recognition by performing a first analysis of the relevant applicable legislation and the alignment of the Institution with the Charter and Code principles. Then, specific Focus Groups were organized in order to involve all personnel and to establish priority actions: Focus Group of administration and structural personnel, Focus Group of predoctoral and postdoctoral researchers and laboratory technicians, Focus Group Tenure Track researchers and Focus Group of researchers. Thanks to the collaboration of these collectives in the Focus Groups, the project has been a very positive and enriching experience. You can find in our website the Action Plan of the accreditation for the next 4 years, and the information about the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers and the Human Resources Strategy for Researchers. </td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTPossible new strategies to combat epithelial metastatic cancer have been described (16/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=63&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0063\2015_0063_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d'Hebron Research Institute (VHIR) includes the latest discoveries in the field of epithelial metastatic cancer and considers the possibility of opening new therapeutic fronts for the treatment of the breast cancer. The article, published in the specialized magazine Current Gene Therapy, focus on the process by which epithelial cells in the body become stem cells, process known as Epithelial Mesenchymal Transition (EMT), and what gene regulation strategy could be used to control this process in tumors, reducing the dangerousness of the breast metastatic cancer. EMT is useful to conceive organs, to regenerate tissues or for the wound healing, but it also plays a very important role in metastatic cancers with an epithelial origin. In this phenomenon, epithelial cancer cells lose their morphological features, acquiring the features of an undifferentiated cell, and get the propriety to survive without being attached to other cells. In consequence, undifferentiated cells are able to detach from the epithelial tissue and travel through the blood to colonize other tissues where they establish and develop the metastasis. Many intracellular changes are necessary for this process, and they are, then, clue elements in the regulation of the tumor’s invasive and metastatic capacity. Some of these regulatory factors are presented in this article as possible therapeutic target, taking into account they have different roles in each kind of tumor and in each tumor’s evolution stage.&nbsp; According to researchers, new methods of gene therapy could allow the modification of these regulatory factors’ expression, keeping the cancer in its early stages, before they become undifferentiated, when the cancer is more sensible to the chemotherapy. This would allow control cancer’s invasive potential and raise the efficacy of the treatment because, often, cells that suffer this phenomenon don’t respond to the pharmacological therapy.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTThe Association for the Familial Hypomagnesemia gives 15,000€ for the research in VHIR (16/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=65&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0065\2015_0065_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Association for the Information and the Research in Familial Hypomagnesemia (HIPOFAM) has given 15,000 euros to the Kidney Physiopatology research group of the Vall d’Hebron Research Institute (VHIR) to investigate this rare disease. With this contribution, the group leaded by Dr Anna Meseguer will hire a junior researcher who will be fully dedicated to the research in Familial Hypomagnesemia, as part of a project coordinated by Dr Gema Ariceta, responsible of the Paediatric Nephrology Service at the Vall d'Hebron University Hospital. The project, funded by the Fondo de Investigación Sanitaria, has the objective of ultrasequencing the RNAm and the microRNAs obtained from exosomes of patients with familial hypomagnesemia, hypercalciuria and nephrocalcinosis with known mutations in the claudina 19 gene. The familial hypomagnesemia affects the kidney because, due to a protein malfunction, the organ doesn’t reabsorb the magnesium. That produces the magnesium is expelled through urine and its blood level is very low. If you want, you can also contribute. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTVHIR leads an international course in sepsis and pneumonia (15/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=64&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0064\2015_0064_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Once again Vall d’Hebron brought together national and international experts in the field of sepsis and pneumonia at the International Course on Antimicrobial Strategies in Infection and Sepsis (ICASIS), hosted in Sitges on April 13th and 14th. In this year’s edition participated professionals from Germany, France, Italy, Belgium, Turkey, Portugal, Switzerland and Spain. Clinicians and researchers discussed the latest advances in innovation and management of patients with serious infections, both from bacterial and fungal origin. In a session coorganized by CIBERBNN and CIBERES , participants talked about the new molecular diagnostics techniques applied to sepsis, including PCR techniques, mass spectrometry and nanotechnology. They also presented clinical cases with innovative treatments by multiresistant bacteria, septic shock complications, and the most recent findings related to biomarkers. The course was chaired by Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis group at Vall d’Hebron Institute of Research (VHIR), and coordinated by Dr. Cristopher Mazo, researcher from the same group. The next edition will be the 30th and 31st of March of 2016 and will be devoted to sepsis in immunocompromised patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Apr 2015 00:00:00 GMTRoche's world leaders visit VHIR (14/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=62&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0062\2015_0062_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Every year Roche organizes a world meeting with all its officers. Two days where the pharmaceutical giant meets to visit one of their offices and reflect on their present and future. In 2015 has arrived the moment to visit Roche Sant Cugat, in Barcelona. In this context we must understand the visit of its top leaders to Vall d'Hebron University Hospital and VHIR. During two hours, within a tight schedule of two days, Roche has decided that one of the activities of its annual meeting would be visiting our hospital and research institute. The reason is easy, Vall d'Hebron is one of the leaders of the pharmaceutical in innovative projects in our country, so that's the reason why the responsible for Roche Spain wanted to show their international colleagues the potential of the collaboration with our campus. The meeting has been chaired by the manager of HUVH, Dr. Vicente Martínez Ibáñez, and the head of research and innovation of the Catalan Ministry of Health, Gabriel Capellá. Also, Ramon Maspons, responsible of Innovation of the Health Quality and Evaluation Agency of Catalunya (AQuAS) made a presentation to inform the responsible of Roche about the data indicating the good work being done in our country related to research and innovation. On the part of Roche have been present the senior management of the Leadership Team, Roland Diggelmann, Division COO, Dan Zabrowski, Global Head Tissue Diagnostics and Jean-Claude Gottraux, Global Head Professional Diagnostics, and other regional leaders to complete twenty representatives. As to VHIR, besides its director, Dr. Joan Comella, who presented the hospital and its research, there were researchers from the liver diseases group. Represented by Dr. Josep Quer, presented a unique breakthrough that will serve to develope a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. On behalf of VHIO, besides the presence of its director, Dr. Josep Tabernero, has intervened Dr. Joaquin Arribas, who presented the possible developments of diagnostic applications based on platforms of new generations of Roche, the basis of RIS3CAT project, in which are jointly working VHIR, VHIO and Roche. "It is a pleasure to visit Barcelona and being able to see first hand the full potential of the relationship between Roche and Vall d'Hebron. We were impressed to see what it's being done and what we can do together in the future," said Roland Diggelmann to close the meeting. </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Apr 2015 00:00:00 GMTThe Bangle, solidarity bracelet with childhood cancer (13/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=61&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0061\2015_0061_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Season's Barcelona, an online jewelry company of Sant Cugat, has launched the solidarity collection Bangle, which consists of several unisex bracelets. 100% of the profits will be for the group of translational research in childhood and adolescence cancer at Vall d'Hebron Institute of Research (VHIR). The initiative has the support of the radio Djs of Los 40 Principales show, Xavier Martinez and Ingrid Sunyer, also from Sant Cugat, who are committed to encouraging young people to contribute to this charity project. The presentation of the collection, which took place at the House of Culture of the Town Hall of Sant Cugat, was chaired by the Deputy Mayor of Citizen Services, Susanna Pellicer, who stressed that "the town hall will promote that many people can buy it and raise funds for research." The head of the research group and of Oncology and Hematology Pediatric Service at Vall d'Hebron University Hospital, Josep Sánchez de Toledo, thanked Season's Barcelona for its commitment. "We are very pleased with this initiative. The money raised will fund one of the three research lines of our laboratory," he said. Meanwhile, the two designers and owners of Season s Barcelona, Charo Álvarez and Ester Guàrdia, explained that "from the moment we founded the company wanted to be involved in helping children and being a responsible company". These jewels, made of gold or leather, cost 20 euros. The purchase can be made through the website of the company. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Apr 2015 00:00:00 GMTDr. Bruno Garcia arrives to Barcelona after 99 days around the world in a boat (10/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=60&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0060\2015_0060_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Bruno is at home. He will have time to rest before rejoining his activity as cardiologist at Vall d'Hebron University Hospital, but yesterday, along with his brother Willy, stepped on dry land after more than 99 days on his boat, We Are Water, with which on Thursday April 9, more than 14 days after the arrival of the winner, finished fifth in the Barcelona World Race. Brothers Bruno and Willy Garcia, an example as sailors and persons were exhausted but elated, happy and satisfied a few minutes after their arrival to the Portal de la Pau, where a crowd were waiting form them on a sunny afternoon in Barcelona. "Going with my little brother has been the biggest success I could ever have. Surely there are better navigators, but I don't have a brother like him, it has been tremendous, tremendous!", assured Bruno with tears in his eyes. More than three months ago we remember the image of the presentation of the boat, the last to be prepared, but good enough to compete with the best. One day late in December, when Bruno posed with the logo of VHIR, which has showed throughout the race with pride for over 23,000 miles in which have suffered many changes in conditions. "You can't imagine how hard it is to endure these conditions with this boat, both the sea and the boat are very demanding, and we have been very fast, but those who have won us have gone even faster, because they are professionals. And I love my profession as much as sailing", says Bruno. For almost one hundred days have brought the solidarity message from We Are Water and Vall d'Hebron Institute of Research on their boat. The experience has made them appreciate the importance of these messages. "I can only say that the world is not as great as we all thought. Because if two brothers as we have been able to get around with a sailboat, which by the way is a wonder, then it's smaller than we think. And therefore, we have to care." Caring for the world and the people who inhabit it. And a message to overcome the daily difficulties. "You miss the fresh food ... a tomato would taste like the glory to me now! But then there aren't so many things that you need, the great lesson is that you can manage yourself without many things." </td></tr></table>comunica@vhir.org (VHIR)Fri, 10 Apr 2015 00:00:00 GMTVHIR talks about research on child cancer at the Live Research Fair (08/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=59&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0059\2015_0059_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Which are the differences of cancer during childhood and adulthood? Why does it take so long for the approval of new drugs? Are there any clinical trials for child cancer? These are some of the questions that the members of the Translational Research in Child and Adolescent Cancer group at VHIR have answered to the students that have visited the Ágora room at the CosmoCaixa. The museum hosts from the 8th to the 11th of April the 13th edition of the Live Research Fair, in which participate 12 Catalan research groups. At Vall d’Hebron’s stand, researchers have 3 posters in which answer some of these questions and describe the experiment that have moved from the laboratory to the fair: a cell proliferation and viability essay. In this experiment, students will test the effect of some drugs, using a simple and quick method, and check its efficacy through the microscope granted by Izasa Scientific. The fair is organized by the Parc Científic de Barcelona, with the support of Obra Social “la Caixa” and the Barcelona city council. The aim of the event is to bring science to society and promote scientific vocations among young people. Posters </td></tr></table>comunica@vhir.org (VHIR)Wed, 8 Apr 2015 00:00:00 GMT